Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group.

Rücker FG, Agrawal M, Corbacioglu A, Weber D, Kapp-Schwoerer S, Gaidzik VI, Jahn N, Schroeder T, Wattad M, Lübbert M, Koller E, Kindler T, Götze K, Ringhoffer M, Westermann J, Fiedler W, Horst HA, Greil R, Schroers R, Mayer K, Heinicke T, Krauter J, Schlenk RF, Thol F, Heuser M, Ganser A, Bullinger L, Paschka P, Döhner H, Döhner K.

Blood. 2019 Nov 7;134(19):1608-1618. doi: 10.1182/blood.2019001425.

PMID:
31554635
2.

Drivers of topoisomerase II poisoning mimic and complement cytotoxicity in AML cells.

More P, Goedtel-Armbrust U, Shah V, Mathaes M, Kindler T, Andrade-Navarro MA, Wojnowski L.

Oncotarget. 2019 Sep 3;10(51):5298-5312. doi: 10.18632/oncotarget.27112. eCollection 2019 Sep 3.

3.

Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML).

Agrawal M, Schwarz P, Giaimo BD, Bedzhov I, Corbacioglu A, Weber D, Gaidzik VI, Jahn N, Rücker FG, Schroeder T, Kindler T, Wattad M, Götze K, Lübbert M, Salwender H, Ringhoffer M, Lange E, Koller E, Thol F, Heuser M, Ganser A, Bullinger L, Paschka P, Döhner H, Geiger H, Borggrefe T, Döhner K, Oswald F.

Leukemia. 2019 Aug 28. doi: 10.1038/s41375-019-0551-4. [Epub ahead of print] No abstract available.

PMID:
31462736
4.

Spatial Chromosome Folding and Active Transcription Drive DNA Fragility and Formation of Oncogenic MLL Translocations.

Gothe HJ, Bouwman BAM, Gusmao EG, Piccinno R, Petrosino G, Sayols S, Drechsel O, Minneker V, Josipovic N, Mizi A, Nielsen CF, Wagner EM, Takeda S, Sasanuma H, Hudson DF, Kindler T, Baranello L, Papantonis A, Crosetto N, Roukos V.

Mol Cell. 2019 Jul 25;75(2):267-283.e12. doi: 10.1016/j.molcel.2019.05.015. Epub 2019 Jun 12.

PMID:
31202576
5.

Requirement for YAP1 signaling in myxoid liposarcoma.

Trautmann M, Cheng YY, Jensen P, Azoitei N, Brunner I, Hüllein J, Slabicki M, Isfort I, Cyra M, Berthold R, Wardelmann E, Huss S, Altvater B, Rossig C, Hafner S, Simmet T, Ståhlberg A, Åman P, Zenz T, Lange U, Kindler T, Scholl C, Hartmann W, Fröhling S.

EMBO Mol Med. 2019 May;11(5). pii: e9889. doi: 10.15252/emmm.201809889.

6.

NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML.

Sasca D, Szybinski J, Schüler A, Shah V, Heidelberger J, Haehnel PS, Dolnik A, Kriege O, Fehr EM, Gebhardt WH, Reid G, Scholl C, Theobald M, Bullinger L, Beli P, Kindler T.

Blood. 2019 May 23;133(21):2305-2319. doi: 10.1182/blood-2018-12-889725. Epub 2019 Feb 27.

PMID:
30814062
7.

Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.

Schlenk RF, Weber D, Fiedler W, Salih HR, Wulf G, Salwender H, Schroeder T, Kindler T, Lübbert M, Wolf D, Westermann J, Kraemer D, Götze KS, Horst HA, Krauter J, Girschikofsky M, Ringhoffer M, Südhoff T, Held G, Derigs HG, Schroers R, Greil R, Grießhammer M, Lange E, Burchardt A, Martens U, Hertenstein B, Marretta L, Heuser M, Thol F, Gaidzik VI, Herr W, Krzykalla J, Benner A, Döhner K, Ganser A, Paschka P, Döhner H; German-Austrian AML Study Group.

Blood. 2019 Feb 21;133(8):840-851. doi: 10.1182/blood-2018-08-869453. Epub 2018 Dec 18.

PMID:
30563875
8.

CHIPing out PPM1D-mutant hematopoiesis.

Kindler T.

Blood. 2018 Sep 13;132(11):1087-1088. doi: 10.1182/blood-2018-07-861716. No abstract available.

PMID:
30213836
9.

Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO).

Nagel G, Weber D, Fromm E, Erhardt S, Lübbert M, Fiedler W, Kindler T, Krauter J, Brossart P, Kündgen A, Salih HR, Westermann J, Wulf G, Hertenstein B, Wattad M, Götze K, Kraemer D, Heinicke T, Girschikofsky M, Derigs HG, Horst HA, Rudolph C, Heuser M, Göhring G, Teleanu V, Bullinger L, Thol F, Gaidzik VI, Paschka P, Döhner K, Ganser A, Döhner H, Schlenk RF; German-Austrian AML Study Group (AMLSG).

Ann Hematol. 2017 Dec;96(12):1993-2003. doi: 10.1007/s00277-017-3150-3. Epub 2017 Oct 31.

10.

DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia.

Gaidzik VI, Weber D, Paschka P, Kaumanns A, Krieger S, Corbacioglu A, Krönke J, Kapp-Schwoerer S, Krämer D, Horst HA, Schmidt-Wolf I, Held G, Kündgen A, Ringhoffer M, Götze K, Kindler T, Fiedler W, Wattad M, Schlenk RF, Bullinger L, Teleanu V, Schlegelberger B, Thol F, Heuser M, Ganser A, Döhner H, Döhner K; German-Austrian Acute Myeloid Leukemia Study Group (AMLSG).

Leukemia. 2018 Jan;32(1):30-37. doi: 10.1038/leu.2017.200. Epub 2017 Jun 23.

PMID:
28643785
11.

Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia.

Jaramillo S, Benner A, Krauter J, Martin H, Kindler T, Bentz M, Salih HR, Held G, Köhne CH, Götze K, Lübbert M, Kündgen A, Brossart P, Wattad M, Salwender H, Hertenstein B, Nachbaur D, Wulf G, Horst HA, Kirchen H, Fiedler W, Raghavachar A, Russ G, Kremers S, Koller E, Runde V, Heil G, Weber D, Göhring G, Döhner K, Ganser A, Döhner H, Schlenk RF.

Blood Cancer J. 2017 May 26;7(5):e564. doi: 10.1038/bcj.2017.45.

12.

CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis.

Fischer J, Paret C, El Malki K, Alt F, Wingerter A, Neu MA, Kron B, Russo A, Lehmann N, Roth L, Fehr EM, Attig S, Hohberger A, Kindler T, Faber J.

J Immunother. 2017 Jun;40(5):187-195. doi: 10.1097/CJI.0000000000000169.

13.

Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.

Wattad M, Weber D, Döhner K, Krauter J, Gaidzik VI, Paschka P, Heuser M, Thol F, Kindler T, Lübbert M, Salih HR, Kündgen A, Horst HA, Brossart P, Götze K, Nachbaur D, Köhne CH, Ringhoffer M, Wulf G, Held G, Salwender H, Benner A, Ganser A, Döhner H, Schlenk RF.

Leukemia. 2017 Jun;31(6):1306-1313. doi: 10.1038/leu.2017.23. Epub 2017 Jan 19.

PMID:
28138160
14.

Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.

Theis F, Corbacioglu A, Gaidzik VI, Paschka P, Weber D, Bullinger L, Heuser M, Ganser A, Thol F, Schlegelberger B, Göhring G, Köhne CH, Germing U, Brossart P, Horst HA, Haase D, Götze K, Ringhoffer M, Fiedler W, Nachbaur D, Kindler T, Held G, Lübbert M, Wattad M, Salih HR, Krauter J, Döhner H, Schlenk RF, Döhner K.

Leukemia. 2016 Nov;30(11):2248-2250. doi: 10.1038/leu.2016.185. Epub 2016 Jul 4. No abstract available.

PMID:
27375010
15.

BAX inhibitor-1 is a Ca(2+) channel critically important for immune cell function and survival.

Lisak D, Schacht T, Gawlitza A, Albrecht P, Aktas O, Koop B, Gliem M, Hofstetter HH, Zanger K, Bultynck G, Parys JB, De Smedt H, Kindler T, Adams-Quack P, Hahn M, Waisman A, Reed JC, Hövelmeyer N, Methner A.

Cell Death Differ. 2016 Feb;23(2):358-68. doi: 10.1038/cdd.2015.115. Epub 2015 Oct 16.

16.

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment.

Gratwohl A, Pfirrmann M, Zander A, Kröger N, Beelen D, Novotny J, Nerl C, Scheid C, Spiekermann K, Mayer J, Sayer HG, Falge C, Bunjes D, Döhner H, Ganser A, Schmidt-Wolf I, Schwerdtfeger R, Baurmann H, Kuse R, Schmitz N, Wehmeier A, Fischer JT, Ho AD, Wilhelm M, Goebeler ME, Lindemann HW, Bormann M, Hertenstein B, Schlimok G, Baerlocher GM, Aul C, Pfreundschuh M, Fabian M, Staib P, Edinger M, Schatz M, Fauser A, Arnold R, Kindler T, Wulf G, Rosselet A, Hellmann A, Schäfer E, Prümmer O, Schenk M, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Büsche G, Haferlach C, Schnittger S, Müller MC, Reiter A, Berger U, Saußele S, Hochhaus A, Hehlmann R; SAKK; German CML Study Group.

Leukemia. 2016 Mar;30(3):562-9. doi: 10.1038/leu.2015.281. Epub 2015 Oct 14.

17.

ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.

Paschka P, Schlenk RF, Gaidzik VI, Herzig JK, Aulitzky T, Bullinger L, Späth D, Teleanu V, Kündgen A, Köhne CH, Brossart P, Held G, Horst HA, Ringhoffer M, Götze K, Nachbaur D, Kindler T, Heuser M, Thol F, Ganser A, Döhner H, Döhner K.

Haematologica. 2015 Mar;100(3):324-30. doi: 10.3324/haematol.2014.114157. Epub 2015 Jan 16.

18.

Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.

Schlenk RF, Kayser S, Bullinger L, Kobbe G, Casper J, Ringhoffer M, Held G, Brossart P, Lübbert M, Salih HR, Kindler T, Horst HA, Wulf G, Nachbaur D, Götze K, Lamparter A, Paschka P, Gaidzik VI, Teleanu V, Späth D, Benner A, Krauter J, Ganser A, Döhner H, Döhner K; German-Austrian AML Study Group.

Blood. 2014 Nov 27;124(23):3441-9. doi: 10.1182/blood-2014-05-578070. Epub 2014 Sep 30.

PMID:
25270908
19.

SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia.

Sasca D, Hähnel PS, Szybinski J, Khawaja K, Kriege O, Pante SV, Bullinger L, Strand S, Strand D, Theobald M, Kindler T.

Blood. 2014 Jul 3;124(1):121-33. doi: 10.1182/blood-2013-11-538819. Epub 2014 May 22.

PMID:
24855208
20.

Radiation sensitivity of human and murine peripheral blood lymphocytes, stem and progenitor cells.

Heylmann D, Rödel F, Kindler T, Kaina B.

Biochim Biophys Acta. 2014 Aug;1846(1):121-9. doi: 10.1016/j.bbcan.2014.04.009. Epub 2014 May 4. Review.

PMID:
24797212
21.

Targeting components of the alternative NHEJ pathway sensitizes KRAS mutant leukemic cells to chemotherapy.

Hähnel PS, Enders B, Sasca D, Roos WP, Kaina B, Bullinger L, Theobald M, Kindler T.

Blood. 2014 Apr 10;123(15):2355-66. doi: 10.1182/blood-2013-01-477620. Epub 2014 Feb 6.

PMID:
24505083
22.

A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course.

Rizzieri D, Vey N, Thomas X, Huguet-Rigal F, Schlenk RF, Krauter J, Kindler T, Gjertsen BT, Blau IW, Jacobsen TF, Johansen M, Bergeland T, Gianella-Borradori A, Krug U.

Leuk Lymphoma. 2014 Sep;55(9):2114-9. doi: 10.3109/10428194.2013.867489. Epub 2014 Jan 24.

PMID:
24255981
23.

Niche-based screening identifies small-molecule inhibitors of leukemia stem cells.

Hartwell KA, Miller PG, Mukherjee S, Kahn AR, Stewart AL, Logan DJ, Negri JM, Duvet M, Järås M, Puram R, Dancik V, Al-Shahrour F, Kindler T, Tothova Z, Chattopadhyay S, Hasaka T, Narayan R, Dai M, Huang C, Shterental S, Chu LP, Haydu JE, Shieh JH, Steensma DP, Munoz B, Bittker JA, Shamji AF, Clemons PA, Tolliday NJ, Carpenter AE, Gilliland DG, Stern AM, Moore MAS, Scadden DT, Schreiber SL, Ebert BL, Golub TR.

Nat Chem Biol. 2013 Dec;9(12):840-848. doi: 10.1038/nchembio.1367. Epub 2013 Oct 27.

24.

Instruction of haematopoietic lineage choices, evolution of transcriptional landscapes and cancer stem cell hierarchies derived from an AML1-ETO mouse model.

Cabezas-Wallscheid N, Eichwald V, de Graaf J, Löwer M, Lehr HA, Kreft A, Eshkind L, Hildebrandt A, Abassi Y, Heck R, Dehof AK, Ohngemach S, Sprengel R, Wörtge S, Schmitt S, Lotz J, Meyer C, Kindler T, Zhang DE, Kaina B, Castle JC, Trumpp A, Sahin U, Bockamp E.

EMBO Mol Med. 2013 Dec;5(12):1804-20. doi: 10.1002/emmm.201302661. Epub 2013 Oct 4.

25.

Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia.

Krönke J, Bullinger L, Teleanu V, Tschürtz F, Gaidzik VI, Kühn MW, Rücker FG, Holzmann K, Paschka P, Kapp-Schwörer S, Späth D, Kindler T, Schittenhelm M, Krauter J, Ganser A, Göhring G, Schlegelberger B, Schlenk RF, Döhner H, Döhner K.

Blood. 2013 Jul 4;122(1):100-8. doi: 10.1182/blood-2013-01-479188. Epub 2013 May 23.

PMID:
23704090
26.

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.

DeAngelo DJ, Spencer A, Bhalla KN, Prince HM, Fischer T, Kindler T, Giles FJ, Scott JW, Parker K, Liu A, Woo M, Atadja P, Mishra KK, Ottmann OG.

Leukemia. 2013 Aug;27(8):1628-36. doi: 10.1038/leu.2013.38. Epub 2013 Feb 6.

PMID:
23385375
27.

STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2.

Tam WF, Hähnel PS, Schüler A, Lee BH, Okabe R, Zhu N, Pante SV, Raffel G, Mercher T, Wernig G, Bockamp E, Sasca D, Kreft A, Robinson GW, Hennighausen L, Gilliland DG, Kindler T.

Cancer Res. 2013 Jan 1;73(1):373-84. doi: 10.1158/0008-5472.CAN-12-0255. Epub 2012 Nov 13.

28.

Novel 3-Azaindolyl-4-arylmaleimides exhibiting potent antiangiogenic efficacy, protein kinase inhibition, and antiproliferative activity.

Ganser C, Lauermann E, Maderer A, Stauder T, Kramb JP, Plutizki S, Kindler T, Moehler M, Dannhardt G.

J Med Chem. 2012 Nov 26;55(22):9531-40. doi: 10.1021/jm301217c. Epub 2012 Nov 2.

PMID:
23088521
29.

Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells.

Lipka DB, Wagner MC, Dziadosz M, Schnöder T, Heidel F, Schemionek M, Melo JV, Kindler T, Müller-Tidow C, Koschmieder S, Fischer T.

PLoS One. 2012;7(7):e40853. doi: 10.1371/journal.pone.0040853. Epub 2012 Jul 16.

30.

JAK2-V617F-mutated myeloproliferative neoplasms reveal different allele burden within hematopoietic cell lineages: a microdissection study of bone marrow trephine biopsies.

Kreft A, Kindler T, Springer E, Kirkpatrick CJ.

Virchows Arch. 2011 Nov;459(5):521-7. doi: 10.1007/s00428-011-1154-2. Epub 2011 Oct 18.

PMID:
22006129
31.

Bioassays to monitor Taspase1 function for the identification of pharmacogenetic inhibitors.

Knauer SK, Fetz V, Rabenstein J, Friedl S, Hofmann B, Sabiani S, Schröder E, Kunst L, Proschak E, Thines E, Kindler T, Schneider G, Marschalek R, Stauber RH, Bier C.

PLoS One. 2011;6(5):e18253. doi: 10.1371/journal.pone.0018253. Epub 2011 May 25.

32.

Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.

Krönke J, Schlenk RF, Jensen KO, Tschürtz F, Corbacioglu A, Gaidzik VI, Paschka P, Onken S, Eiwen K, Habdank M, Späth D, Lübbert M, Wattad M, Kindler T, Salih HR, Held G, Nachbaur D, von Lilienfeld-Toal M, Germing U, Haase D, Mergenthaler HG, Krauter J, Ganser A, Göhring G, Schlegelberger B, Döhner H, Döhner K.

J Clin Oncol. 2011 Jul 1;29(19):2709-16. doi: 10.1200/JCO.2011.35.0371. Epub 2011 May 9.

PMID:
21555683
33.

FLT3 as a therapeutic target in AML: still challenging after all these years.

Kindler T, Lipka DB, Fischer T.

Blood. 2010 Dec 9;116(24):5089-102. doi: 10.1182/blood-2010-04-261867. Epub 2010 Aug 12. Review.

PMID:
20705759
34.

PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors.

Wojiski S, Guibal FC, Kindler T, Lee BH, Jesneck JL, Fabian A, Tenen DG, Gilliland DG.

Leukemia. 2009 Aug;23(8):1462-71. doi: 10.1038/leu.2009.63. Epub 2009 Mar 26.

35.

A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML.

Breitenbuecher F, Markova B, Kasper S, Carius B, Stauder T, Böhmer FD, Masson K, Rönnstrand L, Huber C, Kindler T, Fischer T.

Blood. 2009 Apr 23;113(17):4063-73. doi: 10.1182/blood-2007-11-126664. Epub 2009 Jan 14.

PMID:
19144992
36.

Notch signaling specifies megakaryocyte development from hematopoietic stem cells.

Mercher T, Cornejo MG, Sears C, Kindler T, Moore SA, Maillard I, Pear WS, Aster JC, Gilliland DG.

Cell Stem Cell. 2008 Sep 11;3(3):314-26. doi: 10.1016/j.stem.2008.07.010.

37.

K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.

Kindler T, Cornejo MG, Scholl C, Liu J, Leeman DS, Haydu JE, Fröhling S, Lee BH, Gilliland DG.

Blood. 2008 Oct 15;112(8):3373-82. doi: 10.1182/blood-2008-03-147587. Epub 2008 Jul 28.

38.

The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia.

Kasper S, Breitenbuecher F, Hoehn Y, Heidel F, Lipka DB, Markova B, Huber C, Kindler T, Fischer T.

Leuk Res. 2008 Nov;32(11):1698-708. doi: 10.1016/j.leukres.2008.05.003. Epub 2008 Jun 16.

PMID:
18556063
39.

LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells.

Lipka DB, Hoffmann LS, Heidel F, Markova B, Blum MC, Breitenbuecher F, Kasper S, Kindler T, Levine RL, Huber C, Fischer T.

Mol Cancer Ther. 2008 May;7(5):1176-84. doi: 10.1158/1535-7163.MCT-07-2215.

40.

Cross-inhibition of interferon-induced signals by GM-CSF through a block in Stat1 activation.

Kasper S, Kindler T, Sonnenschein S, Breitenbuecher F, Böhmer FD, Huber C, Fischer T.

J Interferon Cytokine Res. 2007 Nov;27(11):947-59.

PMID:
18052729
41.

Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.

Heidel F, Cortes J, Rücker FG, Aulitzky W, Letvak L, Kindler T, Huber C, Döhner H, Kantarjian H, Fischer T.

Cancer. 2007 Mar 1;109(5):907-14.

42.

Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.

Hess G, Bunjes D, Siegert W, Schwerdtfeger R, Ledderose G, Wassmann B, Kobbe G, Bornhäuser M, Hochhaus A, Ullmann AJ, Kindler T, Haus U, Gschaidmeier H, Huber C, Fischer T.

J Clin Oncol. 2005 Oct 20;23(30):7583-93.

PMID:
16234522
43.

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.

Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, Thiede MH, Brandts C, Serve H, Roesel J, Giles F, Feldman E, Ehninger G, Schiller GJ, Nimer S, Stone RM, Wang Y, Kindler T, Cohen PS, Huber C, Fischer T.

Blood. 2006 Jan 1;107(1):293-300. Epub 2005 Sep 8.

PMID:
16150941
44.

AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.

Choudhary C, Schwäble J, Brandts C, Tickenbrock L, Sargin B, Kindler T, Fischer T, Berdel WE, Müller-Tidow C, Serve H.

Blood. 2005 Jul 1;106(1):265-73. Epub 2005 Mar 15.

PMID:
15769897
45.

Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).

Kindler T, Breitenbuecher F, Kasper S, Estey E, Giles F, Feldman E, Ehninger G, Schiller G, Klimek V, Nimer SD, Gratwohl A, Choudhary CR, Mueller-Tidow C, Serve H, Gschaidmeier H, Cohen PS, Huber C, Fischer T.

Blood. 2005 Jan 1;105(1):335-40. Epub 2004 Sep 2.

PMID:
15345593
46.

Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia.

Kindler T, Breitenbuecher F, Marx A, Beck J, Hess G, Weinkauf B, Duyster J, Peschel C, Kirkpatrick CJ, Theobald M, Gschaidmeier H, Huber C, Fischer T.

Blood. 2004 May 15;103(10):3644-54. Epub 2004 Jan 15.

PMID:
14726395
47.

In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.

Kindler T, Breitenbuecher F, Kasper S, Stevens T, Carius B, Gschaidmeier H, Huber C, Fischer T.

Leukemia. 2003 Jun;17(6):999-1009.

PMID:
12764361
48.

Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.

Kindler T, Breitenbuecher F, Marx A, Hess G, Gschaidmeier H, Gamm H, Kirkpatrick CJ, Huber C, Fischer T.

Blood. 2003 Apr 15;101(8):2960-2. Epub 2002 Dec 12.

PMID:
12480706
49.

BCR-ABL as a target for novel therapeutic interventions.

Kindler T, Meyer RG, Fischer T.

Expert Opin Ther Targets. 2002 Feb;6(1):85-101.

PMID:
11901483
50.

Fatal sepsis due to mycobacterium tuberculosis after allogeneic bone marrow transplantation.

Kindler T, Schindel C, Brass U, Fischer T.

Bone Marrow Transplant. 2001 Jan;27(2):217-8.

Supplemental Content

Loading ...
Support Center